Where does Enyo Pharma rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Enyo Pharma ranks #35,209 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Enyo Pharma hold?

Enyo Pharma holds 7 US utility patents granted between 2022 and 2024, spanning 4 technology areas.

What is Enyo Pharma's Innovation Score?

Enyo Pharma has an Innovation Score of 42.4 out of 100 (top 31% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Enyo Pharma focus on?

Enyo Pharma's top technology area is C07D (Heterocyclic Compounds) with 7 patents. Grants appear in 4 CPC subclasses total.

Is Enyo Pharma's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Enyo Pharma.

What does claim depth mean for Enyo Pharma's patents?

Enyo Pharma's patents average 13.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Enyo Pharma patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Enyo Pharma

USPTO PatentsView assignee record - 7 granted patents across 4 technology areas, recorded in grant years 2022–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Enyo ranks #35,209 of 49,997 tracked US assignees by granted-patent volume, with 7 patents across 4 technology areas.

#35,209
of 49,997 US assignees by volume: Top 31%
by Innovation Score (42.4/100): 13.6
avg claims per patent

USPTO PatentsView assignee plate

Corpus R35209 · Foreign Corporation #35,209 · 7 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 7 grants
MID-PACK #35,209/49,997
PHOTO-FINISH Endostream Medical
CPC-NARROW C07D · 4 areas
INNOV-PAR 42.4/100
CLAIMS-RICH 13.6 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2022–2024 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Endostream Medical Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Enyo Pharma · this assignee

42
3D Lighting… · lowest

7

What this shows Enyo's Innovation Score is 42.4/100 (top 31% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Enyo's grants concentrate

Enyo Pharma is a focused PatentsView assignee: 4 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2024. By volume, Enyo sits between Endostream Medical Ltd. and Eospace Inc..

Enyo's three-year grant acceleration

Enyo Pharma shows 7 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Endostream Medical

7
Enea Agenzia Nazi…

7
Energy Control

7
Enpress

7
Enzymaster (Ningb…

7
Eolas Therapeutics

7
EON Reality

7
Eospace

7
Enyo Pharma ◀

7

What this shows Enyo holds 7 patents at rank #35,148, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Enyo

By rank, the assignees closest to #35,148 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Enyo's primary technology class.

Enyo's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

42 Top 31% higher than 69% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2022–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.

View data table

Enyo Pharma patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2022	2	28.6%
2023	4	57.1%
2024	1	14.3%

Which technologies does Enyo Pharma patent most?

C07D - Heterocyclic Compounds 7

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 3

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 1

Top 4 of 4 technology areas

Where it ranks

Overall rank by patents

#35,209

of 49,997 tracked assignees

Innovation Score

42.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Enyo Pharma's patent record in context - here's where to go next.

Enyo Pharma's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #35,209 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Enyo Pharma against Endostream Medical Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 42.4/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.